# How to Get a GLP-1 Covered by Insurance

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-15 | Updated: 2026-11-10

Canonical page: https://glpwatchdog.org/research/how-to-get-a-glp1-covered-by-insurance

> Coverage is decided in three steps, and most people give up at the wrong one. An exclusion is not the same as a denial, and appealing is worth it for just one of the two.

## Key points

- An EXCLUSION cannot be appealed; a DENIAL can. Establish which you have before spending six weeks on a letter.
- Many employer self-funded plans exclude weight-management drugs as a class.
- Sleep apnea, cardiovascular disease and type 2 diabetes are separate indications with completed outcomes trials, and plans treat them differently from weight alone.
- On a high-deductible plan the cash market can beat the copay until the deductible is met.

Coverage for GLP-1 weight-management drugs is decided in three steps, and most people give up at the wrong one. First, whether your plan covers this category at all. Second, whether you meet the criteria it applies. Third, whether a denial is worth appealing. Sometimes it is not, because an **exclusion** and a **denial** are different things and only one of them can be argued with.

This is the mechanism, in the order it runs, with the questions that get you a straight answer at each stage. It will not promise you approval, but it will tell you quickly whether you are in a fight worth having, so you are not spending six weeks on an appeal against a plan that never covered the category.

## Step one: is the category covered at all?

Before anything else, find out whether your plan excludes weight-management drugs as a class, as [North Carolina’s State Health Plan](https://glpwatchdog.org/research/north-carolina-medicaid-and-state-health-plan-glp1) has since 2024. Many employer plans do, particularly self-funded ones, where [the employer rather than the insurer decides what is covered](https://glpwatchdog.org/research/does-unitedhealthcare-cover-zepbound-and-wegovy) and is paying the claims directly. The same employer choice decides whether a pharmacy benefit manager’s formulary change reaches you, as [CVS Caremark’s Zepbound reversal](https://glpwatchdog.org/research/cvs-caremark-zepbound-coverage) shows. This is the single most important fact and the one most people discover last.

> **An exclusion is not a denial.** A denial says you did not meet the criteria, and criteria can be argued. An exclusion says the benefit does not exist under your plan, and no clinical argument changes that, because the appeal has nothing to overturn. If the category is excluded, your realistic routes are a different indication (below), a manufacturer program, or paying cash. Knowing which situation you are in on day one is worth more than any letter.

> **On Medicare, the rules are different.** Part D cannot cover drugs used for weight loss, but the temporary Medicare GLP-1 Bridge pays for Foundayo, Wegovy and the Zepbound KwikPen at a $50 monthly copay for people who meet its criteria, through December 31, 2027. Type 2 diabetes, moderate-to-severe sleep apnea and fatty liver disease are excluded, because Part D may already cover those.[7] Our [Bridge guide](https://glpwatchdog.org/research/medicare-glp1-bridge) walks through who qualifies.

Ask the member-services line one precise question: *“Does my plan cover drugs for chronic weight management, and if so which ones are on formulary and at what tier?”* Vague questions get vague answers. Ask for it in writing, and ask for the plan document language rather than a summary. For the largest carriers we summarize what each one publishes, such as [UnitedHealthcare’s prior-authorization terms](https://glpwatchdog.org/insurance/united-healthcare) and [Kaiser Permanente’s restricted formularies](https://glpwatchdog.org/insurance/kaiser-permanente), which helps you know what to ask.

While you are on the phone, ask whether your employer or plan sponsors a weight program outside the drug benefit. [FlyteHealth](https://glpwatchdog.org/reviews/flytehealth), for example, sells physician-led cardiometabolic care to employers, payers and health plans, prescribes a GLP-1 only when it fits, and says most of the medication it uses is not a GLP-1.

## Step two: the criteria, and the diagnosis that changes them

Where the category is covered, it almost always sits behind prior authorization, meaning your prescriber has to justify the prescription before the plan will pay. The criteria vary by plan, but they are usually built from the same parts: a BMI threshold, sometimes a weight-related condition alongside it, sometimes documented prior attempts at weight loss, and sometimes [a requirement to try a cheaper drug first](https://glpwatchdog.org/research/does-kaiser-cover-zepbound-and-wegovy). A prescriber who bills your plan does that paperwork for you; our board of [GLP-1 providers that take insurance](https://glpwatchdog.org/best/glp1-providers-that-take-insurance) lists the online sellers whose own descriptions say they accept or coordinate it.

- **BMI threshold.** Commonly 30, or 27 with a weight-related condition. That is the same structure the pivotal trials used for enrollment.
- **Documented prior attempts.** Some plans want a record of supervised weight-management effort. If you have one, it belongs in the request; if you do not, ask what counts before assuming you fail.
- **Step therapy.** Trying an older or cheaper drug first, usually [Contrave or Qsymia](https://glpwatchdog.org/compare/drugs/contrave-vs-qsymia). This is common and it is appealable when the required drug is contraindicated for you or has already failed.
- **Continuation criteria.** Approval is often for a limited period with a weight-loss threshold to renew. Ask what that threshold is at the start rather than discovering it at month six.

The most consequential point in this step: **a different indication is a different conversation.** Obstructive sleep apnea, established cardiovascular disease and type 2 diabetes each have completed outcomes trials behind them, and plans treat them differently from weight alone. If you have one of these, or suspect you might (sleep apnea in particular is widely undiagnosed), raise it with your clinician before a weight-based request is filed. [Our trial pages](https://glpwatchdog.org/research/trials) set out what each of those indications rests on.

## Step three: if it is denied

1. **Get the reason in writing.** A denial notice must state a reason. That reason determines everything that follows, and a phone summary of it is not good enough.
2. **Check whether it is an exclusion or a criteria failure.** If the plan excludes the category, stop and change route. If you missed a criterion, find out precisely which one.
3. **Fix the specific gap.** Missing documentation is the most common and most fixable reason: a prior attempt that was not recorded, a comorbidity not coded, a BMI from the wrong date.
4. **Ask for a peer-to-peer review.** Your prescriber speaks to the plan’s reviewing clinician directly. It is often faster and more effective than a written appeal, and many prescribers will do it if asked.
5. **Escalate to external review if internal appeals fail.** Most plans are subject to an independent external review, which is decided outside the insurer.[3] It is not a formality, and it is not universally available, so ask whether your plan is subject to it.

> **A letter is easier to send than to write.** Our [prior-authorization letter generator](https://glpwatchdog.org/tools/glp1-prior-auth-letter-generator) assembles a request from your details for your prescriber to review and sign, and the [employer coverage checker](https://glpwatchdog.org/tools/insurance-employer-checker) and [state Medicaid checker](https://glpwatchdog.org/tools/state-medicaid-glp1-checker) cover the two questions people most often get wrong about their own plan.

## When cash beats the copay

Coverage is not automatically the cheaper route, and this is the arithmetic people skip. On a high-deductible plan you may pay the full brand price, frequently over $1,000 a month, until the deductible is met. Against that, when this guide was written in August 2026, compounded cash prices in this register ran from about $79 a month for semaglutide and $99 for tirzepatide, with medians near $190 and $264. The manufacturers now sell the approved drugs for cash too. The Wegovy pill starts at $149 a month and Foundayo at $149.[4][5] A Zepbound KwikPen runs $299 at the starting dose and $699 at the top three doses at the regular price.[6]

That is not an argument for skipping insurance; a met deductible and a $25 copay beats everything. It is an argument for doing the sum before you assume, and, for anyone uninsured on a low income, for checking the [manufacturers’ free-medicine programs](https://glpwatchdog.org/research/glp1-patient-assistance-programs) first. Our guide to [the cash market](https://glpwatchdog.org/research/cheapest-glp1-without-insurance) sets out what the compounded route involves, including what you give up.

If you end up paying cash, pre-tax money may still apply. [Woodwork](https://glpwatchdog.org/reviews/woodwork), [Harbor](https://glpwatchdog.org/reviews/harbor) and [LifeVine Wellness](https://glpwatchdog.org/reviews/lifevine-wellness) list HSA/FSA eligibility, and so do [Rila](https://glpwatchdog.org/reviews/rila) and [AVArx](https://glpwatchdog.org/reviews/avarx). [FormidableMD](https://glpwatchdog.org/reviews/formidablemd), which bills per visit in four states, and [Blis MD](https://glpwatchdog.org/reviews/blis-md), which sells one month at a time, list it as well. [TrimRx](https://glpwatchdog.org/reviews/trimrx) takes eligible HSA and FSA cards and also offers installment plans through Affirm, Klarna and Afterpay. Our [ranking of HSA and FSA semaglutide sellers](https://glpwatchdog.org/best/semaglutide-providers/with-hsa) covers sellers that name those accounts in their published terms. Your account administrator has the final word on what it will reimburse.

Check what an eligible charge pays for, too. [Genesis Health](https://glpwatchdog.org/reviews/genesis) lists FSA/HSA eligibility, and its plans fold the doctor visit and coaching into the monthly price instead of billing them separately. [Collective](https://glpwatchdog.org/reviews/collective) is also advertised as HSA/FSA eligible, but its $59 monthly price for compounded semaglutide leaves out the $199 annual membership it requires.

Insurance can also cover the visit when the drug is a separate question. [Doctronic](https://glpwatchdog.org/reviews/doctronic) charges your copay, or $39 without insurance, for a video visit, and its doctors send a Wegovy or Zepbound prescription to your own pharmacy, where your plan’s coverage sets what the medication costs.

## Common questions

## Frequently asked questions

### How do I get Wegovy or Zepbound covered by insurance?

Confirm first that your plan covers weight-management drugs at all, since many employer plans exclude the category. If it does, expect prior authorization: your prescriber submits clinical justification, typically against a BMI threshold with or without a weight-related condition, and sometimes a step-therapy requirement. Ask member services for the criteria in writing before the request is filed rather than after it is denied.

### What is the difference between a denial and an exclusion?

A denial means you did not meet the plan's criteria, and criteria can be appealed. An exclusion means the benefit does not exist under your plan at all, and an appeal has nothing to overturn. This distinction decides whether an appeal is worth your time, and it is the first thing to establish.

### Does having sleep apnea or heart disease help?

It can change the question entirely. Zepbound carries an FDA indication for obstructive sleep apnea and Wegovy one for cardiovascular risk reduction, both backed by completed outcomes trials. A plan that excludes weight-management drugs may still cover a drug prescribed for one of those. It is worth raising with your clinician before a weight-based request goes in.

### How long does prior authorization take?

For commercial and marketplace plans, federal rules give the insurer up to 15 days to decide a prior authorization, or 72 hours when care is urgent. When you ask about turnaround, ask for the appeal deadline too. Appeal windows are finite, and they are the thing people most often miss.

### Can I appeal a step-therapy requirement?

Often yes. Step therapy is generally appealable where the required drug is contraindicated for you, has already failed, or is expected to be ineffective given your history. That is a clinical argument your prescriber makes, and it is one of the more winnable appeals.

### Will a manufacturer savings card help if I have no coverage?

Usually not. The Wegovy and Zepbound savings cards require commercial insurance and exclude anyone on Medicare, Medicaid, VA or TRICARE. What exists for cash payers is the manufacturers' own direct programs, plus the compounded market this register tracks. As of October 2026 the direct prices run from $149 a month for the starting doses of the Wegovy pill and Foundayo to $699 for the highest Zepbound KwikPen doses at the regular price.

## References

1. U.S. National Library of Medicine WEGOVY (semaglutide) injection — prescribing information, including approved indications. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=WEGOVY
2. U.S. National Library of Medicine ZEPBOUND (tirzepatide) injection — prescribing information, including the obstructive sleep apnea indication. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ZEPBOUND
3. Centers for Medicare & Medicaid Services Appeals in a health plan — internal appeals and external review. HealthCare.gov. 2026. https://www.healthcare.gov/appeal-insurance-company-decision/appeals/
4. Novo Nordisk Wegovy savings offer — self-pay prices for Wegovy pill and Wegovy injection. NovoCare. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html
5. Eli Lilly and Company Foundayo (orforglipron) — LillyDirect self-pay prices by dose. LillyDirect. 2026. https://www.lilly.com/lillydirect/foundayo
6. Eli Lilly and Company Zepbound savings and self-pay — regular price for a 1-month supply of Zepbound single-patient-use KwikPen. Lilly. 2026. https://zepbound.lilly.com/savings
7. Centers for Medicare & Medicaid Services Weight loss drugs — Medicare GLP-1 Bridge coverage, eligibility, covered drugs and costs. Medicare.gov. 2026. https://www.medicare.gov/coverage/weight-loss-drugs

---

Cite as: GLP Watchdog, Nora Bissett, "How to Get a GLP-1 Covered by Insurance", published 2026-08-15, updated 2026-11-10. https://glpwatchdog.org/research/how-to-get-a-glp1-covered-by-insurance

Canonical HTML page: https://glpwatchdog.org/research/how-to-get-a-glp1-covered-by-insurance

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
